Sound Pharmaceuticals, Inc.

Developer of ebselen (SPI-1005), an oral antioxidant that holds FDA Breakthrough Therapy Designation for hearing loss in Meniere's disease though a dedicated tinnitus-dose trial underperformed placebo, and of SPI-5557, an earlier-stage regenerative candidate for inner-ear structures.